---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016981"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:59:54.459295+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain

## Summary
- Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.
- Non-cash gain of $365.4M from fair value increase in GMP Bio JV investment, partially offset by $111.6M deferred tax provision.
- JV subsidiaries Sapu Bio and Sapu Nano formalized; OT-101 Phase 1 combo trial completed and Phase 2/3 pancreatic cancer enrolling.
- Deciparticle nanoparticle platform advancing six candidates; everolimus trial enrolling in Australia, INDs expected for palbociclib and docetaxel in 2026.
- PDAOAI AI platform expanded to over 100,000 curated abstracts, contributing to seven peer-reviewed publications in 2025.

## SEC filing metadata
- accession: 0001493152-26-016981
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/0001493152-26-016981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016981
- JSON: https://secwatch.observer/filing/0001493152-26-016981.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.